Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
Lung cancer is a devastating illness with an overall poor prognosis. To effectively address this disease, early detection and novel therapeutics are required. Early detection of lung cancer is challenging, in part because of the lack of adequate tumor biomarkers. The goal of this review is to summarize the knowledge of current biomarkers in lung cancer, with a focus on important serum biomarkers. The current knowledge on the known serum cytokines and tumor biomarkers of lung cancer will be presented. Emerging trends and new findings in the search for novel diagnostic and therapeutic tumor biomarkers using proteomics technologies and platforms are emphasized, including recent advances in mass spectrometry to facilitate tumor biomarker discovery program in lung cancer. It is our hope that validation of these new research platforms and technologies will result in improved early detection, prognostication, and finally the treatment of lung cancer with potential novel molecularly targeted therapeutics.
Bharti
Ajit
A
Center for Molecular Stress Response Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Ma
Patrick C
PC
Salgia
Ravi
R
D014408:Biomarkers, Tumor / Q000032:analysis*; D003936:Diagnosis, Computer-Assisted / Q000639:trends; D005544:Forecasting; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D013058:Mass Spectrometry / Q000639:trends*; D009363:Neoplasm Proteins / Q000032:analysis*; D020543:Proteome / Q000032:analysis*; D040901:Proteomics / Q000639:trends*
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D020543:Proteome